0J8P Stock Chart & Stats
$558.63
$12.56(2.26%)
At close: 4:00 PM EDT
$558.63
$12.56(2.26%)
Day’s Range― - ―
52-Week Range$499.99 - $771.52
Previous CloseN/A
Volume303.00
Average Volume (3M)185.00
Market Cap
$41.14B
Enterprise Value$42.65K
Total Cash (Recent Filing)$196.93M
Total Debt (Recent Filing)$1.10B
Price to Earnings (P/E)36.6
Beta0.86
Next Earnings
Nov 03, 2026EPS Estimate
3.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)14.24
Shares Outstanding78,781,110
10 Day Avg. Volume186
30 Day Avg. Volume185
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)33.75
Price to Sales (P/S)12.59
P/FCF Ratio51.44
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$699.17Price Target Upside25.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)14.77
Revenue Forecast (FY)$4.72B
Bulls Say, Bears Say
Bulls Say
Recurring Diagnostics GrowthStrong recurring diagnostics growth demonstrates durable demand and pricing capability beyond one-time instrument sales. The installed analyzer base, consumable pull-through, and integrated workflows can support repeat revenue, customer retention, and continued expansion over the next several quarters.
Margins And Cash GenerationHigh margins combined with substantial free cash flow indicate a scalable operating model and strong earnings quality. This financial capacity supports research, commercial investment, debt management, and shareholder returns while preserving flexibility if market conditions soften.
Product InnovationAdoption of newer diagnostic platforms expands IDEXX’s addressable opportunity and reinforces its role in veterinary workflows. Successful placements can create future consumable demand, deepen customer integration, and provide multiple avenues for durable growth beyond the existing product base.
Bears Say
U.S. Visit PressureLower clinic and wellness visit volumes can reduce testing activity and constrain customer demand, particularly where diagnostic utilization is linked to patient encounters. Continued discretionary spending pressure and slower pet additions could keep visit-driven revenue growth below its longer-term potential.
Foreign-Exchange ExposureIDEXX’s international operations expose reported results to currency movements that management cannot fully offset through operating execution. Persistent dollar strength can reduce translated revenue and earnings, complicating growth comparisons and limiting the conversion of underlying international demand into reported results.
Investment-Driven Cost PressureHigher commercial, research, and technology spending may strengthen future products and capabilities, but it also creates near-term pressure on operating leverage. If incremental investments take longer to produce returns, expense growth could temper margin expansion and reduce the pace of earnings growth.
Idexx Laboratories News
0J8P FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest share price was $499.99 and its highest was $771.52 in the past 12 months.
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is $41.14B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Nov 03, 2026 which is in 32 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on Aug 04, 2026. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.943 by $0.327.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 3.71.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 78,781,110 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $4.27 in its last earnings report, beating expectations of $3.943. Following the earnings report the stock price went up 5.275%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Currently, no hedge funds are holding shares in GB:0J8P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Idexx Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$699.17 (25.16% Upside)
$699.17 (25.16% Upside)
Blogger Sentiment
Bullish
GB:0J8P Sentiment 73%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Idexx Laboratories
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
0J8P Company Deck
0J8P Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly constructive operational and financial picture: solid organic revenue growth (~9% Q2), recurring CAG Diagnostics strength, robust margin and EPS expansion, strong free cash flow and aggressive capital returns, plus clear product and innovation momentum (inVue Dx, Cancer Dx, Catalyst SDMA). Offsetting items include continued pressure on U.S. clinic and wellness visits, a Q2 instrument revenue lap effect, foreign-exchange headwinds, and planned incremental investments that will temper near-term margin gains. Overall, the positive drivers — durable recurring revenue expansion, margin gains, cash generation, and multiple innovation milestones — materially outweigh the cited headwinds.View all GB:0J8P earnings summaries0J8P Revenue Breakdown
91.86% CAG
4.67% Water
3.06% LPD
0.41% Other
0J8P Stock 12 Month Forecast
Average Price Target
$699.17
▲(25.16% Upside)